A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 22, 2018

Primary Completion Date

June 1, 2022

Study Completion Date

July 8, 2022

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AK105

Anti-PD-1 antibody; IV infusion, 200 mg Q3W

DRUG

Anlotinib Hydrochloride

multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off

Trial Locations (1)

Chinese PLA General Hospital, Beijing